Tamr Submits IPO Prospectus Highlighting Role in White House Cancer Moonshot Initiative

In late January this year, U.S. President Barack Obama announced the establishment of a special Moonshot task force, led by Vice President Joe Biden. This initiative aims to shorten the timeline for cancer cure research and accelerate progress in cancer prevention, treatment, and cures by removing certain bureaucratic obstacles. Biden stated that the greatest challenge lies in addressing the siloing of clinical data, and he called for the integration of data and research findings across the entire scientific community. This call resonated with Tamr, as it aligns precisely with what this big-data integration startup is doing.

The U.S. government’s online news portal published an initiative titled “White House Cancer Moonshot Task Force.” The article outlined the rationale for launching this effort: “Cancer is currently a leading cause of death, and global cancer incidence is projected to continue rising in the coming decades. We are now on the cusp of major breakthroughs in cancer research, which is of critical importance to our nation.”



Tamr, a startup dedicated to solving data connectivity and diverse integration challenges at commercial scale with speed and efficiency, was founded in 2013 in Cambridge, Massachusetts, by several veterans of the database industry. The founding team includes co-founders Andy Palmer, Mike Stonebraker, and Ihab Ilyas, all formerly affiliated with MIT CSAIL (Massachusetts Institute of Technology Computer Science and Artificial Intelligence Laboratory). Notably, Mike Stonebraker, a towering figure in the field of modern databases, was awarded the Turing Award in 2014.

On March 21, Tamr published an open letter to Vice President Biden on its official website, aiming to support the Cancer Moonshot initiative. Tamr identified data standardization and data integration as two major obstacles to this U.S. anti-cancer effort. By the end of this year, the U.S. Food and Drug Administration (FDA) will require that data records from medical experiments comply with CDISC standards, which will facilitate the submission, acquisition, exchange, and archiving of clinical study data and metadata. However, historical evidence has shown that converting clinical care data into the CDISC format consumes substantial human and financial resources, significantly hindering data analysis and interpretation. In light of this, Tamr offered three recommendations to the White House in its open letter:

I. Data regulation should avoid conventional approaches.

The idea of establishing a federal agency akin to the U.S. Food and Drug Administration or the U.S. Department of Health and Human Services to facilitate data acquisition and exchange is outdated. Instead, a “SpaceX”-style initiative could be launched, partnering with government entities—both public and private—as well as cancer centers, pharmaceutical firms, and technology companies. This approach would align the Moonshot initiative with the interests of all stakeholders, enabling data acquisition at optimal speed and with maximal innovative capacity.

II. First, address the issues of operability and standardization.

Most cancer research institutions cannot even access all the data they have already been studying, let alone effectively exchange data with external parties. Therefore, this action plan aims to break down the information silos existing among hundreds, or even thousands, of enterprises.

III. Invest in Today’s Technology for Tomorrow.

From an operational perspective, we leverage machine learning technologies like Tamr to automate data preparation and integration within vast datasets. When issues arise that machines cannot resolve automatically, data experts can intervene manually to obtain feedback and further optimize the system. This approach assists thousands of scientific researchers and groups in classifying and integrating their data, enabling them to better understand their informational “treasure troves.”

Tamr stated that it hopes to leverage its expertise and technological advantages in the big data field to bolster the Moonshot Initiative, ultimately helping to achieve the White House’s goal of “ending cancer as we know it.”

Tamr’s technology can be applied to a wide range of organizations, including information service providers, pharmaceutical companies, and retailers. The company completed its Series B financing last June, raising a total of $41.2 million from nine investors, including Google Ventures and New Enterprise Associates.